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 3 
Abstract (250/250 words) 43 
Background: High cryptococcal antigen (CrAg) titers in blood are associated with subclinical meningitis 44 
and mortality in CrAg-positive individuals with advanced HIV-disease (AHD). We evaluated a novel semi-45 
quantitative lateral flow assay (LFA), CryptoPS, that may be able to identify individuals with high CrAg 46 
titers in a cohort of AHD patients undergoing CrAg screening.  47 
Methods: In a prospective cohort of patients with AHD (CD4 ≤200 cells/µL) receiving CD4 count testing, 48 
CryptoPS and IMMY LFA CrAg testing were performed on whole blood by two operators blinded to 49 
results of the other assay. Sensitivity, specificity, positive predictive value (PPV), and negative predictive 50 
value (NPV) of CryptoPS were assessed against IMMY LFA as a reference. CryptoPS low-titer (T1 band) 51 
and high-titer (T2 band) results were compared against IMMY LFA titers obtained through serial dilution.  52 
Results: 916 specimens were tested. Sensitivity of the CryptoPS assay was 61.0% (25/41, 95% confidence 53 
interval [95%CI]: 44.5-75.8), specificity 96.6% (845/875, 95%CI: 95.1-97.7), PPV 45.5% (95%CI: 32.0-54 
59.4), and NPV 98.1% (95%CI: 97.0-98.9). All (16/16) CryptoPS false-negatives were samples with IMMY 55 
titers ≤1:160. Of 29 patients (30 specimens) who tested positive on CryptoPS but negative on IMMY LFA, 56 
none developed cryptococcal meningitis over 3-months follow-up without fluconazole. Median CrAg 57 
titers were 1:20 (interquartile range [IQR] 0-1:160) in CryptoPS T1-positive samples and 1:2560 (IQR 58 
1:1280-1:10240) in T2-positives.  59 
Conclusions: Diagnostic accuracy of the CryptoPS assay was sub-optimal in the context of CrAg 60 
screening, with poor sensitivity at low CrAg titers. However, the CryptoPS assay reliably detected 61 
individuals with high titers associated with poor outcomes.   62 
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 4 
Introduction 63 
Cryptococcal meningitis (CM) remains a major cause of mortality in persons living with HIV (PLWH), 64 
causing an estimated 15% of HIV-related deaths worldwide (1). In individuals with advanced HIV disease 65 
(AHD), detection of cryptococcal antigen (CrAg) in the blood has been shown to precede the 66 
development of CM (2, 3). CrAg screening in patients with AHD starting antiretroviral therapy (ART), 67 
with targeted pre-emptive fluconazole  in CrAg-positives, has been shown to reduce incident CM and all-68 
cause mortality (4), and is recommended by the World Health Organization (WHO) in those starting or 69 
reinitiating ART with a CD4 T-cell count <200 cells/µL (5). 70 
 Pre-emptive fluconazole therapy for CrAg-positive individuals reduces but does not completely 71 
eliminate excess mortality (6); up to one-third of asymptomatic CrAg-positive patients with AHD have 72 
disseminated central nervous system (CNS) disease and may require more potent antifungal regimens 73 
for effective treatment (5-7). Higher CrAg titers (>1:160) are associated with increased risk of CNS 74 
disease and death in CrAg-positive individuals (7-9). Titers can be assessed through serial dilution using 75 
commercial assays, but this requires extended labor and additional costs making it impractical in 76 
resource-limited settings. Semi-quantitative CrAg assays may provide a simpler means of stratifying risk 77 
for CrAg-positive patients with AHD and guiding differentiated treatment strategies.  78 
CryptoPS (Biosynex, Strasbourg, France) is a semi-quantitative immunochromatographic assay 79 
that detects all Cryptococcus neoformans/gattii serotypes and provides results within 10 minutes. The 80 
assay has a control band, qualitative T1 band for CrAg-positivity, and semi-quantitative T2 band 81 
indicating a “high” CrAg titer (Figure 1). Just two limited diagnostic evaluations have been reported to 82 
date (10, 11). In a small study of patients with a CD4 <100 cells/µL in Cameroon, CryptoPS had good 83 
agreement with a commercial lateral flow assay (LFA) (IMMY diagnostics, Norman, Oklahoma, USA) and 84 
enzyme immunoassay (EIA) [Premier CrAg, Meridian Bioscience, Inc. Newtown, OH, USA], with a median 85 
reciprocal EIA titer >1:160 correlating with T2 band positivity; although the sample size which included 86 
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 5 
just 14 serum CrAg-positive patients limited estimates of precision (10). A second study testing 99 87 
archived serum samples selected from a cohort of HIV-positive Ugandans undergoing CrAg screening 88 
reported similar findings, with reasonable agreement between the CryptoPS and IMMY LFA and median 89 
CrAg titers of 1:320 in those with T2 band positivity (11); however, this study was also limited by a small 90 
sample size. CryptoPS was not tested on whole blood samples likely to be beneficial for point-of-care 91 
testing in either study; and the assay has not been evaluated prospectively and under routine care 92 
conditions.  93 
 We investigated diagnostic performance of the CryptoPS assay in a prospective CrAg screening 94 
cohort in Botswana, evaluating test accuracy (sensitivity, specificity, positive predictive value [PPV], 95 
negative predictive value [NPV]) against a validated reference standard. To determine titer cutoffs for 96 
the CryptoPS T2 band (high-titer), we compared CryptoPS readings with IMMY CrAg titer results by serial 97 
dilution.  98 
 99 
Materials and Methods 100 
From January 2018 - January 2019, we performed real-time CrAg testing on EDTA whole blood samples 101 
from a sequential cohort of individuals with CD4 ≤200 cells/µL undergoing routine reflex CrAg screening 102 
at the Botswana-Harvard HIV Reference Laboratory (BHHRL). The BHHRL performs all CD4 testing for 27 103 
ART clinics and a central referral hospital located around Gaborone. The full cohort has been described 104 
in detail elsewhere (12); briefly, CD4 T-cell count testing was performed using flow cytometry 105 
(FACSCalibur, Becton, Dickinson and Company, Franklin Lakes, NJ, USA); residual EDTA blood from 106 
sequential samples with a CD4 ≤200 cells/µL was screened for CrAg in real-time using the IMMY LFA 107 
(IMMY, Norman, OK, USA) as a validated reference standard (13, 14). CryptoPS testing was performed 108 
by a second trained operator blinded to IMMY LFA results. Results were interpreted by visual reading as 109 
negative (only control band visualized), T1 band positive (with control and T1 bands visualized by the 110 
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operator), or T2 band positive (control, T1, and T2 bands visualized), as per manufacturer’s instructions 111 
(Figure 1).   112 
As the CryptoPS is not registered for diagnostic use in Botswana, all clinical management 113 
decisions were based on IMMY LFA results. IMMY LFA positive patients were managed according to the 114 
Botswana National HIV Management Guidelines (15). Individuals who tested positive by CryptoPS but 115 
negative by the IMMY LFA were contacted by the study team for re-testing by IMMY LFA and monitored 116 
over 3 months to evaluate for development of incident CM but did not receive antifungal therapy unless 117 
the repeat IMMY LFA results were positive. Three-month outcomes in these individuals with positive 118 
CryptoPS but negative IMMY LFA results were assessed through telephone contact, review of a national 119 
electronic medical records system, review of clinical notes, or further contact with clinical providers as 120 
needed. 121 
At the end of the study period, IMMY LFA titers were determined by serial dilution of plasma 122 
samples stored at -80 Celsius. To enable further validation of the CryptoPS semi-quantitative results, 123 
we used both the CryptoPS and IMMY LFA to test an additional collection of 141 archived known CrAg-124 
positive plasma samples from: 1) patients in a CrAg screening cohort from 2015-2016 (8); and 2) patients 125 
with CM enrolled in a completed phase II clinical trial evaluating induction therapies (16). All CrAg 126 
testing was performed by laboratory scientists blinded to previous testing results. 127 
 Finally, to better characterize samples with discordant CryptoPS and IMMY LFA test results, we 128 
re-tested all discordant samples with Meridian’s CrAg EIA [Meridian Bioscience, Cincinnati, OH] and 129 
IMMY’s EIA (IMMY, Norman, OK) at the National Institute for Communicable Diseases (NICD) in 130 
Johannesburg, South Africa. This study was approved by institutional review boards at the Botswana 131 
Ministry of Health and Wellness, the University of Botswana, Princess Marina Hospital, and the 132 
University of Pennsylvania.  133 
Statistical analysis.  134 
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 7 
In the prospective CrAg screening cohort, we determined the sensitivity, specificity, PPV, and NPV of the 135 
CryptoPS assay with 95% confidence intervals (95%CI) using the IMMY LFA assay as a reference 136 
standard. Using all CrAg-positive samples from the prospective screening cohort, plus the additional 137 
archived CrAg-positive samples, we evaluated the median and interquartile range of dilutional IMMY 138 
LFA CrAg titer values in samples with CryptoPS that were T1 band and T2 band positive, and displayed 139 
results graphically. 140 
Laboratory findings, including the results of cryptococcal EIA testing, were described in samples with 141 
discordant CryptoPS/LFA results, and clinical outcomes reported in individuals with negative IMMY LFA 142 
but positive CryptoPS results. Analyses were performed using Stata Version 16 (College Station, TX, 143 
USA).  144 
 145 
Results 146 
Sensitivity and specificity of CryptoPS in a sequential cohort of individuals with CD4 ≤200 cells/µL  147 
Nine-hundred and sixteen sequential blood samples were tested with the IMMY LFA and CryptoPS CrAg 148 
assays from 870 unique patients (46 had repeat CD4 testing and reflex CrAg screening, Table 1); median 149 
age was 39 years (interquartile range [IQR]: 33-46), 58.4% (507/868, 2 missing data) were male, and the 150 
median CD4 count was 142 cells/µL (IQR: 85-174 cells/µL). Using IMMY LFA testing, 41 of the 916 151 
samples were CrAg-positive (4.5%, 95% confidence interval [CI]: 3.2-6.0%) with a median CrAg titer of 152 
1:80 (IQR: 1:20 to 1:960). Using the IMMY LFA as the reference standard, the CryptoPS sensitivity was 153 
61.0% (95%CI: 44.5-75.8%), and specificity was 96.6% (95%CI: 95.1-97.7%), yielding a PPV of 45.5% 154 
(95%CI: 32.0-59.4%) and NPV of 98.1% (95%CI: 97.0-98.9%) in our cohort (Table 2).  155 
The CryptoPS assay was positive in 55/916 (6.0%, 95%CI: 4.6-7.7%) of samples; 25/55 (45.5%) 156 
were IMMY LFA positive and classified as “true positives” (18 T1 band and 7 T2 band). The remaining 157 
30/55 (54.5%) CryptoPS positives were IMMY LFA negative and classified as “false-positives” (29 T1 band 158 
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 8 
and 1 T2 band). On confirmatory testing, all 30 of the CryptoPS false-positives were Meridian EIA 159 
negative, and 29/30 were IMMY EIA negative, with one low-level positive (Figure 2a). Sixteen samples 160 
were IMMY LFA positive but CryptoPS-negative and classified as “false-negatives”; all had IMMY LFA 161 
CrAg titers ≤1:160, and 13 of the 16 had titers ≤1:40. Three of the sixteen were only LFA positive in the 162 
lowest dilution tested (1:2) and negative on the IMMY EIA (Figure 2b). 163 
 Detailed characteristics of the 30 false-positive CryptoPS results are shown in Table 3. The thirty 164 
“false-positive” CryptoPS samples were from 29 patients (one had two tests); 79% (23/29) received 165 
repeat IMMY LFA testing of whom 100% (23/23) were CrAg-negative. Most (97%, 28/29) were on ART at 166 
the time of CrAg screening and none received pre-emptive fluconazole. None (0/29) were diagnosed 167 
with cryptococcal meningitis in the 3 months following CD4 testing and reflex CrAg screening, and 28/29 168 
were alive at completion of follow-up. One patient died 5 days after the date of CD4 testing after 169 
presenting to hospital with a clinical diagnosis of a lower respiratory tract infection; no central nervous 170 
system infection was suspected and the patient did not receive a lumbar puncture as part of his 171 
diagnostic evaluation. The patient’s CryptoPS result was T1 band positive, with negative IMMY LFA, 172 
IMMY EIA, and Meridian EIA.  173 
 Given the relatively low sensitivity and specificity of the CryptoPS assay on EDTA whole blood, 174 
we repeated CryptoPS testing on frozen plasma samples after study completion blinded to previous 175 
results, which yielded very similar results to real-time whole blood testing for these specimens (Table 176 
S1).  We also repeated the analysis restricted to individuals with CD4 cell counts ≤100 cells/µL; in this 177 
subgroup the sensitivity of the CryptoPS was 83.3% (95% CI: 58.6-96.4%) and specificity was 96.5% (95% 178 
CI: 93.5-98.4%) (Table S2). 179 
 180 
Relationship between CryptoPS bands and dilutional CrAg titers 181 
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 9 
Combining the samples from the sequential CrAg screening cohort with 141 archived IMMY LFA CrAg-182 
positive blood samples, 870 were CryptoPS negative, 102 samples were T1 band positive, and 84 were 183 
T2 band positive (one CryptoPS T2 positive individual in the sequential cohort did not have sufficient 184 
residual plasma for titration). The median IMMY LFA titer of the T1 band positive samples was 1:20 (IQR: 185 
LFA negative to 1:160). Median titers in the CryptoPS T2 band positive samples were 1:2560 (IQR: 186 
1:1280 to 1:10240); 79/84 (94%) of T2 positive samples had titers of ≥1:160 (Figure 3).   187 
 188 
Discussion 189 
In this prospective evaluation of the novel semi-quantitative CryptoPS CrAg LFA in HIV-seropositive 190 
individuals with CD4 ≤200 cells/µl undergoing CrAg screening, we found sub-optimal assay sensitivity of 191 
the CryptoPS assay compared to an established CrAg LFA (IMMY). The lower sensitivity of the CryptoPS 192 
was exclusively due to false-negative test results on blood samples with low CrAg titers; all samples with 193 
a titer of >1:160 were detected by the assay.  194 
Our study adds to two prior small diagnostic validation studies of the CryptoPS assay. A study of 195 
stored serum samples from Cameroon found a test sensitivity of 78% (11/14) against the IMMY LFA (10). 196 
The median CD4 count of samples in this study was lower than in our cohort (44 cells/µL versus 142 197 
cells/µL), likely resulting in a higher median CrAg titer (1:160 versus 1:80) and contributing to slightly 198 
higher observed sensitivity (12). A second study of 99 cryopreserved serum samples from a Ugandan 199 
CrAg screening cohort found a CryptoPS assay sensitivity of 88% (50/57, 95%CI: 76%-95%) and specificity 200 
of 95% (40/42, 95%CI: 84%-99%) against the IMMY LFA; however, only 65% of samples with an IMMY 201 
LFA dilutional titer of ≤1:20 were positive on the CryptoPS assay (11). Similarly, in our prospective 202 
evaluation all (16/16) false-negative whole blood CryptoPS results were on samples with CrAg titers 203 
≤1:160, 13 (81%) with titers ≤1:40. These patients may be at relatively low risk for progression to 204 
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 10 
meningitis in the absence of pre-emptive fluconazole, assuming prompt initiation or continuation of 205 
effective ART (17).  206 
While the CryptoPS assay had sub-optimal overall sensitivity, the T2 band performed well in 207 
discriminating samples that had high CrAg titers with greater risk of meningitis and or failure of 208 
fluconazole pre-emptive therapy (6), with 79/84 (94%) of T2 band positive samples from stored blood 209 
found to have titers of  ≥1:160 by serial dilution. The assay may have clinical utility in recognizing CrAg-210 
positive patients who require further diagnostic evaluation for meningitis and enhanced antifungal 211 
treatment, albeit at the expense of missing a proportion of patients with lower CrAg titers who are still 212 
likely to benefit from standard pre-emptive fluconazole treatment (18). To avoid missing these 213 
individuals with lower titers, the CryptoPS could be used as a second test, performed after an initial 214 
IMMY LFA screen, to identify the highest risk individuals with T2 bands for enhanced care. The ease of 215 
use and interpretation of the CryptoPS tests may make this an attractive strategy in some settings. 216 
 We found moderate specificity of the CryptoPS assay, in keeping with the previous study from 217 
Uganda but with greater estimated precision given our larger sample size (11). We carefully followed the 218 
29 patients with presumed false-positive CryptoPS results (positive CryptoPS result and negative IMMY 219 
LFA) for a period of at least 3 months. All patients (23/29) with repeat IMMY LFA testing again tested 220 
negative, all were negative with secondary testing using the Meridian EIA and all but one with the IMMY 221 
EIA. None developed meningitis despite receiving no antifungal treatment, supporting classification of 222 
these tests as false-positives. Further, nearly all were confirmed to be alive over follow-up; one patient 223 
died shortly after screening, but for causes likely unrelated to cryptococcal disease. Given a relatively 224 
low prevalence of cryptococcal antigenemia in patients with AHD (19), the positive predictive value of 225 
the CryptoPS assay in the prospective cohort was below 50%, with more false-positive than true positive 226 
results.  227 
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 11 
 Our study is subject to several limitations. Cryptococcus spp. isolates have significant serotype 228 
diversity within Southern Africa, which may impact test sensitivity (20, 21). Although the CryptoPS assay 229 
can detect all Cryptococcus neoformans/gattii serotypes, different genotypic and phenotypic 230 
characteristics of local fungi could potentially have impacted test performance. Secondly, although 231 
IMMY LFA and CryptoPS tests were read by trained laboratory operators blinded to testing results on 232 
the other assay, we did not have two independent reviewers read the CryptoPS assay to evaluate inter-233 
rater reliability. However, we repeated CryptoPS testing on the same stored plasma specimens with 234 
similar test results, and all IMMY LFA-positive samples underwent further testing through serial dilution 235 
confirming positive results, so findings are highly likely to be valid.  236 
 In summary, the CryptoPS assay provides rapid semi-quantitative CrAg test results on whole 237 
blood specimens and good discrimination for high-titer results. Limitations in sensitivity and specificity 238 
may limit its use clinically in cryptococcal antigen screening programs which typically aim to detect 239 
individuals with relatively low cryptococcal antigen burdens. These limitations may be less marked when 240 
testing individuals with suspected cryptococcal meningitis who have a higher pre-test probability of 241 
infection and higher blood CrAg titers. 242 
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Figure Legend 339 
Figure 1. CryptoPS semi-quantitative assay. 20 µL of blood specimen are added to the collection well of 340 
the cassette followed by 3 drops of sample diluent with the result read at 10 minutes. A. Negative result 341 
(control band positive); B. Low-titer positive (T1 and control bands positive); C. High-titer positive (T1, T2, 342 
and control bands positive). Patient initials and study identification codes written on the bottoms of the 343 
test strips have been concealed to ensure anonymity of the research participants. 344 
 345 
Figure 2. Discordant CryptoPS and IMMY LFA results. (A) CryptoPS “false-positive” results with secondary 346 
testing using the IMMY EIA; 29/30 samples tested negative on the IMMY EIA at an optical density below 347 
positive cutoff and one sample tested positive at an optical density of 0.625. All samples tested negative 348 
using the Meridian EIA. (B) CryptoPS “false-negative” results completed to IMMY LFA dilutional titer and 349 
IMMY EIA optical density; 16/16 samples had an IMMY LFA titer of ≤1:160 and 3 tested negative on the 350 
IMMY EIA at an optical density below positive cutoff, all 3 were IMMY LFA positive only in undiluted 351 
samples indicating very low titers. 352 
 353 
Figure 3. Comparison of CryptoPS titer results and dilutional titers obtained using the IMMY LFA. The 354 
violin plots show the distribution of dilutional CrAg titers in CryptoPS negative, T1 (low titer), and T2 (high 355 
titer) samples; 916 prospectively screened samples and 141 additional archived CrAg-positive plasma 356 
samples. 25 CryptoPS negative samples (16 from the prospective cohort and 9 archived samples) were 357 
positive on IMMY testing, all at titers of ≤1:160. 29 CryptoPS T1 positive and 1 CryptoPS T2 positive 358 
samples were IMMY LFA negative. Median titers in the T1 and T2 groups with interquartile ranges are 359 
shown on the figure. Note that in the treatment trial from which some of the archived samples were from 360 
the maximum dilutional titer measured was 1:2560, hence some titers at this level may have been higher 361 
if further dilutions were performed.  362 
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Figure 1.  370 
 371 
372 
  373 
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Figure 2. 374 
 375 
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 377 
 378 
Figure 3. 379 
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Table 1. Baseline characteristics of study participants 384 
Variable Value (median, IQR or %, n) 
Sequential cohort of individuals with CD4 cell counts ≤200 cells/µL screened for CrAg  
(916 samples from 870 individuals)* 
Age (years)† 39 years (IQR 33-46) 
Sex (% male)† 58% (507/868†) 
CD4 count (cells/µL)§ 142 cells/µL (IQR 86-174) 
Cryptococcal antigenemia** (% positive)§ 4.5% (n=41) 
ART status (% on ART)§ 75% (n=691/916) 
Prior cryptococcal meningitis (%)† 1% (n=13/870) 
Additional individuals included in titer validation cohort  
(all CrAg-positive, n=141)** 
Age (years) 38 years (IQR 32-44) 
Sex (% male) 58% (81/139†) 
CD4 count (cells/µL) 31 cells/µL (IQR 12-63) 
Cryptococcal antigenemia** (% positive) 100% (n=141) 
ART = antiretroviral therapy; CrAg = cryptococcal antigen; IQR = interquartile range; LFA = lateral flow assay 385 
* 916 samples tests on 870 unique patients ; 46 individuals had repeat samples 386 
† Age data were missing for 2 individuals. Age, sex, and prior cryptococcal meningitis data are reported for the 870 387 
individuals in the CrAg screening cohort at the time of their first CrAg test 388 
§  Shows CD4 counts, IMMY CrAg LFA result, and ART status at the time of testing (some patients were tested twice 389 
during screening period); of 226 patients not on ART at date of CD4 testing, 17% (39) had defaulted ART and 83% 390 
(187) had no prior history of ART use 391 
** CrAg results obtained using the IMMY CrAg lateral flow assay 392 
  393 
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Table 2. Sensitivity, specificity, positive, and negative predictive value of the CryptoPS semi-quantitative 394 
assay versus the conventional IMMY LFA test, whole blood samples. 395 
  IMMY LFA +ve IMMY LFA -ve Total 
 CryptoPS +ve 25 30 55 
 CryptoPS -ve 16 845 861 
 Total 41 875 916 
Sensitivity 61.0% 95% CI 44.5% - 75.8% 
Specificity 96.6% 95% CI 95.1% - 97.7% 
Positive predictive value 45.5% 95% CI 32.0% - 59.4% 
Negative predictive value 98.1% 95% CI 97.0% - 98.9% 
CI = confidence interval; LFA = lateral flow assay; SQ = semi-quantitative, +ve = positive; -ve = negative 396 
  397 
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Table 3. Clinical characteristics and outcomes of patients with false-positive CryptoPS tests on whole blood specimens. 398 
Case Age Sex CD4 
count, 
cells/
µL 
On ART Prior 
CM 
Repeat 
IMMY LFA  
Received 
antifungal 
therapy 
Incident 
CM 
within 3 
months 
Death 
within 3 
months 
Comments 
1 53 Male 169 Yes No Negative No No No  
2 65 Male 106 Yes No Negative No No No  
3 40 Female 25 Yes No Negative No No No  
4 48 Female 145 Yes No Negative No No No  
5 50 Female 106 Yes No Negative No No No  
6 24 Female 44 Yes No Negative No No No  
7 31 Female 83 Yes No Negative  No No No  
8 37 Female 161 Yes No Negative No No No  
9 41 Male 115 Yes No Negative No No No  
10 7 Male 197 Yes No Negative No No No  
11 19 Male 143 Yes No Negative  No No No  
12 43 Female 158 Yes No Negative No No No  
13 41 Male 32 Yes No Negative No No No  
14 19 Female 147 Yes No Negative No No No  
15 24 Male 134 Yes No Negative No No No  
16 32 Male 149 Yes No Negative No No No  
17 36 Female 103 Yes No Negative No No No  
18 48 Male 194 Yes No Negative No No No  
19 42 Male 106 Yes No Negative No No No  
20 32 Female 68 Yes No Negative No No No  
21 52 Female 193 Yes No Negative No No No  
22* 45 Male 98 Yes No Negative No No No Lumbar puncture and CSF testing for cryptococcus 
(by CSF India ink and culture) 31 days after HIV test 
date, all CSF tests negative 
23 33 Male 86 Defaulted No Negative No No No Re-started ART, CD4 increased to 156 cells/µL and 
HIV viral load 652 copies/µL 133 days after first CD4 
test. 
24 39 Female 83 Yes No Not 
performed 
No No No Moved from Gaborone and unable to repeat IMMY 
LFA; re-established care in Gaborone with HIV-clinic 
visit 308 days after CrAg test, no cryptococcal 
meningitis diagnosed during follow-up. 
25 39 Male 125 Yes No Not 
performed 
No No No Unable to contact for repeat CrAg testing; attended 
HIV-clinic visit 287 days after CrAg test, no 
cryptococcal meningitis diagnosed during follow-up. 
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26 20 Female 190 Yes No Not 
performed 
No No No Unable to contact for repeat CrAg testing; HIV-clinic 
visit 363 days after CrAg test, no cryptococcal 
meningitis diagnosed during follow-up. 
27 unknown Male 171 Yes No Not 
performed 
No No No Participant unable to meet with study team for re-
testing but asymptomatic; repeat CD4 testing at 61 
days from first test showed CD4 of 271 cells/µL and 
HIV viral load <400 copies/mL. 
28 29 Female 125 Yes No Not 
performed 
No No No Unable to contact patient; seen in clinic 37 days 
after CD4 test date and was stable without reported 
symptoms and HIV viral load <400 copies/mL; no 
subsequent laboratory evaluation for CM or 
documentation of death from national death 
registry. 
29 51 Male 32 Yes No Not 
performed 
No No Yes Presented to referral hospital Emergency 
department 5 days after CD4 and CrAg test date; 
vomiting, anorexia, wasting with dehydration. 
Admission diagnosis of pneumonia and/or 
pulmonary tuberculosis, anemia, and renal failure. 
Died the following day; no clinical evidence of 
meningitis and no lumbar puncture and CSF 
evaluation performed; unlikely to have died from 
CM. 
ART = antiretroviral therapy; CrAg = cryptococcal antigen; CM = cryptococcal meningitis; CSF = cerebrospinal fluid; LFA = lateral flow assay 399 
* Patient had two positive CryptoPS test results 400 
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See Supplementary Materials File for tables S1 and S2  401 
 on D
ecem
ber 11, 2020 at S
T
 G
E
O
R
G
E
'S
 LIB
R
A
R
Y
http://jcm
.asm
.org/
D
ow
nloaded from
 
 on D
ecem
ber 11, 2020 at S
T
 G
E
O
R
G
E
'S
 LIB
R
A
R
Y
http://jcm
.asm
.org/
D
ow
nloaded from
 
0
.1
.2
.3
.4
.5
.6
.7
.8
.9
1
IM
M
Y
 C
rA
g
 E
IA
 O
D
 r
e
s
u
lt
 (
u
n
it
s
)
 T1 (low)  T2 (high)  
CryptoPS Result
IMMY LFA +ve IMMY LFA -ve 
CryptoPS +ve 25 30 
CryptoPS -ve 16 845 
(3)
1
2
3
IM
M
Y
 C
rA
g
 E
IA
 O
D
 r
e
s
u
lt
 (
u
n
it
s
)
1:1 1:5 1:10 1:20 1:40 1:80 1:1601:2
IMMY LFA Titer
A. 
B. 
16 “False Negatives” 
30 “False Positives” 
 on D
ecem
ber 11, 2020 at S
T
 G
E
O
R
G
E
'S
 LIB
R
A
R
Y
http://jcm
.asm
.org/
D
ow
nloaded from
 
Negative T1 T2
Negative
1:2
1:5
1:10
1:20
1:40
1:80
1:160
1:320
1:640
1:1280
1:2560
1:5120
1:10240
1:20480
1:40960
1:81920
1:163840
1:327680
1:655360
CryptoPS Result
IM
M
Y
 L
F
A
 C
rA
g
 T
ite
r
845 29 1
Median 1:20
(IQR 0 - 1:160)
Median 1:2560
(IQR 1:1280 - 1:10240)
 on D
ecem
ber 11, 2020 at S
T
 G
E
O
R
G
E
'S
 LIB
R
A
R
Y
http://jcm
.asm
.org/
D
ow
nloaded from
 
